Gsa Capital Partners LLP Fennec Pharmaceuticals Inc. Transaction History

Gsa Capital Partners LLP

  • $1.32 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021
SELL
$6.51 - $9.62 $447,393 - $661,124
-68,724 Closed
0 $0
Q2 2021

Aug 05, 2021
BUY
$5.96 - $7.85 $192,215 - $253,170
32,251 Added 88.42%
68,724 $501,000
Q1 2021

May 10, 2021
BUY
$6.21 - $8.68 $226,497 - $316,585
36,473 New
36,473 $226,000
Q4 2020

Feb 03, 2021
SELL
$5.99 - $8.55 $134,086 - $191,391
-22,385 Closed
0 $0
Q3 2020

Nov 06, 2020
BUY
$5.19 - $10.17 $116,178 - $227,655
22,385 New
22,385 $136,000

Others Institutions Holding FENC

# of Institutions
64
Shares Held
14.8M
Call Options Held
10K
Put Options Held
83.8K
View Full List

About FENNEC PHARMACEUTICALS INC.

FENC Quotes by TradingView
  • Ticker FENC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,067,300
  • Market Cap $115M
  • Description
  • Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...
More about FENC
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email